Navigation Links
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Date:10/8/2008

LYON, France, Oct. 8 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL) today is presenting expanded clinical data and new nonclinical data demonstrating that the company's Vaxfectin(R) adjuvant may be broadly applicable in DNA- and protein-based infectious disease vaccines and peptide-based cancer vaccines. Alain P. Rolland, Pharm.D., Ph.D., Vical's Senior Vice President of Product Development, will present the data today, Wednesday, October 8, at the World Vaccine Congress (Lyon, France - October 6-9).

Vaxfectin(R)-formulated Cancer Vaccines

In a mouse study, a Vaxfectin(R)-formulated vaccine containing a peptide from Tyrosinase-Related Protein 2 (TRP-2), an antigen commonly expressed by several types of tumors including glioma and melanoma, resulted in approximately a 100-fold increase in antigen-specific CD8+ T-cell responses compared with unformulated vaccine. CD8+ T-cells are deployed by the immune system to identify and destroy infected or cancerous cells.

Vaxfectin(R)-formulated Protein Vaccines

Vical has previously reported that data from studies in mice demonstrated the potential of the Vaxfectin(R) adjuvant to be used as a dose-sparing agent with protein-based commercial seasonal influenza vaccine and with protein-based H5N1 pandemic influenza vaccine currently stockpiled by the U.S. government. Vaxfectin(R)-formulated vaccine produced higher antibody responses than up to 10-fold higher doses of unformulated vaccine. Dose-sparing could be critical in extending limited vaccine supplies to protect the greatest number of people in the event of a pandemic influenza outbreak.

Data from additional studies in mice presented for the first time today demonstrated that Vaxfectin(R)-formulated seasonal in
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015  SillaJen, Inc., a ... of oncolytic immunotherapy products for cancer, today announced ... the Annual Meeting of the American Association for ... murine adapted version of its lead product candidate, ... is an oncolytic immunotherapy designed to 1) rapidly ...
(Date:4/20/2015)... , April 20, 2015 The preclinical contract research ... testing of drugs and safety testing of medical devices, announces ... at this week,s workshop " Drug Transporters in ADME: From ... MD . The title of Dr. Hidalgo,s talk is ... a session entitled "Transporter Tools of the Future." ...
(Date:4/20/2015)... , April 20, 2015   Gateway ... Research and Training Institute today expanded its Naloxone: ... outpatient locations.  A $50,000 grant from the ... research project possible.  The yearlong ... to patients and their family members upon completion ...
Breaking Medicine Technology:SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 2SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 3Absorption Systems Chief Scientist Ismael Hidalgo to Present at International Workshop on Drug Transporters 2Gateway Rehab and the Kenneth S. Ramsey, PhD Research and Training Institute expand Naloxone: Increasing Access, Saving Lives research project to outpatient locations 2Gateway Rehab and the Kenneth S. Ramsey, PhD Research and Training Institute expand Naloxone: Increasing Access, Saving Lives research project to outpatient locations 3
... Calif., Dec. 4 Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) ... Amended Plan of Reorganization and related amended Disclosure Statement with ... , A hearing to consider the adequacy of ... with the hearing on the confirmation of the Plan scheduled ...
... , EMERYVILLE, Calif., Dec. 4 ... it will host an investor teleconference and webcast. Principal ... and/or refractory multiple myeloma, as featured at the 51st American ... begin at 9:00 a.m. CT/10:00 a.m. ET on Monday, December ...
Cached Medicine Technology:Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2
(Date:4/20/2015)... Bronx, NY (PRWEB) April 20, 2015 The ... are introducing the community to Bella Diosa Laser Med Spa ... invited to a spa party on from 12–7 p.m. on ... The event will include drinks and refreshments. Participants will also ... Attendees will receive a free gift with any purchase, as ...
(Date:4/20/2015)... is a seemingly idyllic and tranquil island oasis in ... off the southeastern coast of Africa, the tiny nation ... everyone lives together in harmony. , But the shimmering ... drug abuse. In fact, it carries a dubious designation: ... in eastern Africa. , “Many youngsters, they know the ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 At the ... held the “RockNRolla Movie Awards” EcoLuxe Lounge, with Choices ... Angeles’ leading producer of sustainable product placement in TV ... of socially conscious and ecologically sound goods and services ... star Chase Masterson hosted the Choices Celebrity Interview Lounge, ...
(Date:4/20/2015)... Connecticut (PRWEB) April 20, 2015 ... Moreen Donahue, DNP, RN, NEA-BC, FAAN who was ... Nursing Education and Research in September 2014, is ... Nursing Officer to lead the development of Western ... this newly created role, Donahue will be responsible ...
(Date:4/20/2015)... 2015 The normal response from the doctor ... we could do.” Especially if the patient sought medical care ... should be much different. So it’s critical the patient’s loved ... be done?” , Not every emergency room physician or ... can be done.” But, according to Ronald P. Benitez ...
Breaking Medicine News(10 mins):Health News:Bella Diosa Says Hello to Yonkers Community with Spa Party 2Health News:Voice For Humanity: Choolun Bhojoo leads the fight to rid Mauritius of a drug plague 2Health News:Choices Recovery South Bend Talks About Healthy Decisions with TV's Adrienne Janic 2Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 3
... ... wellness. Learn how to improve the look and strength of your abdominal muscles and improve ... on this new Web site. , ... June 17, 2010 -- A new Web site has been developed to help anyone get in ...
... ... to Bring Fresh, Locally Sourced, All-Natural Snacks and Beverages to Kicks 4 Kids Community ... ... First Soccer and the McHenry Area Soccer Federation have partnered with McHenry’s Healthy U ...
... now new areas in which whole body magnetic resonance imaging ... Deutsches rzteblatt International ( Dtsch Arztebl Int 2010; ... of possible uses, together with the limits of this radiation-free ... routine use in hospitals, as the procedure takes less than ...
... is a great deal of interest in factors that contribute ... One factor that appears to contribute to the heritable ... codes for the serotonin transporter, also known as the serotonin ... transporter gene appears to increase one,s risk for depression and ...
... role of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein ... a robust, non-invasive predictor of cardiovascular (CV) risk in ... by the results of a multinational study presented today ... League Against Rheumatism in Rome, Italy. The presence ...
... Grant to ... Athletes , ... June 17, 2010 -- Athletes for Hope (AFH), an entrepreneurial non-profit founded by 12 of ... purpose of inspiring all athletes to engage in positive social impact, has been awarded a ...
Cached Medicine News:Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 2Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 3Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 4Health News:PTSD: The serotonin system influences vulnerability and treatment 2Health News:NT-proBNP is a predictor of CV risk in arthritis patients taking NSAIDs 2Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 2Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 3
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Disposable Cannula Cuffless Tracheostomy Tubes...
Indications For Usage: ,For use with percutaneous tracheotomies...
Disposable Cannula Cuffed Tracheostomy Tubes...
Medicine Products: